Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30(3):454–60.
Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 2014;27(4):647–64.
Kaasch AJ, Barlow G, Edgeworth JD, Fowler Jr VG, Hellmich M, Hopkins S, et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014;68(3):242–51.
Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65(6):1135–44.
Marples RR, Heaton CL, Kligman AM. Staphylococcus aureus in psoriasis. Arch Dermatol. 1973;107(4):568–70.
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–60.
Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 1996;34(5 Pt 2):911–4.
Loulergue P, Tubach F, Salmon D, Dellamonica P, Taillan B, Thorel JB, et al. Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect. 2013;67(6):524–8.
Correr CJ, Rotta I, Teles TS, Godoy RR, Riveros BS, Garcia MM, et al. Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. Cad Saude Publica. 2013;29 Suppl 1:S17–31.
Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51.
Liu Y, Gong JP, Li WF. Therapeutic effect and safety of ustekinumab for plaque psoriasis: a meta-analysis. Chin Med Sci J. 2014;29(3):131–8.
Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K et al. Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol 2015.
Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54.
Toussirot E, Michel F, Bereau M, Binda D. Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient Prefer Adherence. 2013;7:369–77.
Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–45.
Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–74.
Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974–80.
Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.
Trinchieri G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol. 1997;9(1):17–23.
Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.
Carvalho BT, Iazzetti AV, Ferrarini MA, Campos SO, Iazzetti MA, Carlesse FA. [Salmonella septicemia associated with interleukin 12 receptor beta1 (IL-12Rbeta1) deficiency]. J Pediatr (Rio J). 2003;79(3):273–6.
Diniz LM, Guimaraes T, Oliveira M, Pinto JA, Miranda SS. Lymphadenitis caused by infection with an isoniazid- and rifampin-resistant strain of Mycobacterium bovis BCG in an infant with IFN-gamma/IL-12 pathway defect. J Bras Pneumol. 2014;40(2):188–92.
Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest. 2010;120(5):1762–73.
Balci DD, Duran N, Ozer B, Gunesacar R, Onlen Y, Yenin JZ. High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis. Eur J Dermatol. 2009;19(3):238–42.
Dubost JJ, Soubrier M, Sauvezie B. Pyogenic arthritis in adults. Joint Bone Spine. 2000;67(1):11–21.
Favero M, Schiavon F, Riato L, Carraro V, Punzi L. Septic arthritis: a 12 years retrospective study in a rheumatological university clinic. Reumatismo. 2008;60(4):260–7.
Gomez RN, Ibanez RJ, Gonzalez M, Pintado A, Penelas CY. Peripheral septic arthritis in adults. Epidemiologic study in a Galician health area. An Med Interna. 2001;18(11):573–7.